StockData

TG Therapeutics vs Travere Therapeutics

TGTX and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How TGTX and TVTX compare

TG Therapeutics is the larger company, worth 2.0 times as much as Travere Therapeutics ($9.6B against $4.8B).

Travere Therapeutics grew revenue faster over the last twelve months (77.1% versus 76.1% for TG Therapeutics).

TG Therapeutics keeps more of each dollar of sales as profit, with a net margin of 55.2% compared with −7.4% at Travere Therapeutics.

TG Therapeutics scores higher on the StockData Score (9 against 6 for Travere Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricTGTXTVTX
Size and price
Market cap$9.6B$4.8B
Share price$62.71$51.10
Change, 1 year102%48.1%
Change, 5 years162%76.0%
Beta (5Y)0.471.91
Employees399497
StockData Score
Total score9 (better)6
Valuation score1 (better)0
Growth score23 (better)
Performance score4 (better)2
Health score2 (better)1
Dividend score00
Valuation
P/E22.9×–
P/S12.0×8.1× (better)
P/B15.9× (better)196×
EV/EBITDA71.3× (better)197×
P/FCF552×–
FCF yield0.18%–
Fair value$60.66$6.01
Margin of safety−3.4% (better)−751%
Growth
Revenue growth (TTM)76.1%77.1% (better)
Revenue growth, 5Y average427% (better)19.9%
Net income growth (TTM)630%–
EPS growth (TTM)641%–
Profitability
Gross margin82.4%98.6% (better)
Operating margin17.1% (better)−6.8%
Net margin55.2% (better)−7.4%
FCF margin2.2%–
Return on equity100% (better)−152%
Return on invested capital27.8%–
Financial health
Debt / equity1.23–
Net debt / EBITDA0.98–
Interest coverage3.6× (better)−4.3×
Current ratio4.27 (better)4.05
Altman Z-score6.07 (better)2.29
Piotroski F-score47 (better)
Dividends and buybacks
Buyback yield1.9%–
Shareholder yield1.9% (better)0.00%
Ownership
Held by institutions72.6%112%
Held by insiders16.1%1.6%
Insider net buying, 12 months−$275K (better)−$110M
Short interest, % of float22.4%10.3%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.